EBS vs ZOM ᐉ Comparison: Which is Better to Invest?
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and ZOM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 1 FA rating(s) are green whileZOM’s FA Score has 0 green FA rating(s).
- EBS’s FA Score: 1 green, 4 red.
- ZOM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 4 TA indicator(s) are bullish while ZOM’s TA Score has 4 bullish TA indicator(s).
- EBS’s TA Score: 4 bullish, 4 bearish.
- ZOM’s TA Score: 4 bullish, 5 bearish.
Price Growth
EBS (@Pharmaceuticals: Other) experienced а +24.15% price change this week, while ZOM (@Pharmaceuticals: Other) price change was -1.88% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.75%. For the same industry, the average monthly price growth was +5.58%, and the average quarterly price growth was -5.21%.
Reported Earning Dates
EBS is expected to report earnings on Feb 22, 2024.
ZOM is expected to report earnings on Feb 28, 2024.
Industries' Descriptions
@Pharmaceuticals: Other (+4.75% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| EBS | ZOM | EBS / ZOM | |
| Capitalization | 107M | 167M | 64% |
| EBITDA | -343.2M | -11.94M | 2,876% |
| Gain YTD | -78.239 | 2.638 | -2,966% |
| P/E Ratio | 17.73 | N/A | - |
| Revenue | 1.07B | 24M | 4,475% |
| Total Cash | 88.6M | 106M | 84% |
| Total Debt | 903M | 1.75M | 51,541% |
EBS | ZOM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 92 | |
PRICE GROWTH RATING 1..100 | 65 | 71 | |
P/E GROWTH RATING 1..100 | 12 | 100 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZOM's Valuation (53) in the Pharmaceuticals Major industry is in the same range as EBS (66) in the Biotechnology industry. This means that ZOM’s stock grew similarly to EBS’s over the last 12 months.
ZOM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EBS (100) in the Biotechnology industry. This means that ZOM’s stock grew similarly to EBS’s over the last 12 months.
ZOM's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as EBS (97) in the Biotechnology industry. This means that ZOM’s stock grew similarly to EBS’s over the last 12 months.
EBS's Price Growth Rating (65) in the Biotechnology industry is in the same range as ZOM (71) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to ZOM’s over the last 12 months.
EBS's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for ZOM (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew significantly faster than ZOM’s over the last 12 months.
| EBS | ZOM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 78% |
| MACD ODDS (%) | N/A | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 80% |
| Advances ODDS (%) | 1 day ago 74% | 16 days ago 83% |
| Declines ODDS (%) | 8 days ago 85% | 6 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 84% | N/A |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| EKBDX | 11.76 | N/A | N/A |
| Allspring Diversified Cap Bldr Adm | |||
| PGSVX | 10.49 | N/A | N/A |
| Pioneer Global Sustainable Value A | |||
| MGQLX | 17.22 | -0.07 | -0.40% |
| Morgan Stanley Inst Global Sustain L | |||
| BTIRX | 181.65 | -0.99 | -0.54% |
| DWS Equity 500 Index R6 | |||
| CABGX | 16.85 | -0.18 | -1.06% |
| Multi-Manager Growth Strategies Inst 3 | |||